These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 6319248

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems.
    Hirohashi M, Takasuna K, Kasai Y, Usui C, Kojima H.
    Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569
    [Abstract] [Full Text] [Related]

  • 3. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
    Shintani S, Toba Y, Suzuki S, Ninomiya S, Umezato M, Hiyama T.
    Arzneimittelforschung; 1985 Jan; 35(7A):1157-62. PubMed ID: 4074429
    [Abstract] [Full Text] [Related]

  • 4. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
    Hirotsu I, Kihara T, Nakamura S, Hattori Y, Hatta M, Kitakaze Y, Takahama K, Hashimoto Y, Miyata T, Ishihara T.
    Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K, Fujita S, Umezato M, Hosoki E, Toba Y, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M, Yajima M, Nishimura T, Ikeda H, Nishimori T.
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [Abstract] [Full Text] [Related]

  • 9. [Effects of ritodrine hydrochloride on motor nervous system and central nervous system].
    Ikeda S, Tsukamoto T.
    Nihon Yakurigaku Zasshi; 1984 Sep; 84(3):311-26. PubMed ID: 6500405
    [Abstract] [Full Text] [Related]

  • 10. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, Shimomura K.
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [Abstract] [Full Text] [Related]

  • 11. [Pharmacological studies on oxatomide. (5). Effect on the central and peripheral nervous systems].
    Ohmori K, Ishii H, Shuto K, Nakamizo N.
    Nihon Yakurigaku Zasshi; 1983 Mar; 81(3):245-66. PubMed ID: 6134657
    [Abstract] [Full Text] [Related]

  • 12. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
    Hirohashi M, Takasuna K, Tamura K, Yamaguchi K, Maekawa K, Yamada S, Iwasaki S, Yoshida M, Nomura M, Taguchi K.
    Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
    [Abstract] [Full Text] [Related]

  • 13. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G, Morimoto S, Shiomi M.
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [Abstract] [Full Text] [Related]

  • 14. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
    Murata T, Sakaya S, Hoshino T, Umetsu T, Hirano T, Nishio S.
    Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
    [Abstract] [Full Text] [Related]

  • 15. [Pharmacological properties of procaterol, a newly synthetized, specific beta 2-adrenoceptor stimulant. Part I. Effects on the CNS (author's transl)].
    Hashimoto K, Shintani S, Yamashita S, Tei S, Takai M, Tsutsui M, Kawamura K, Ohkawa T, Hiyama T, Yabuuchi Y.
    Nihon Yakurigaku Zasshi; 1979 Apr 20; 75(3):271-89. PubMed ID: 43821
    [Abstract] [Full Text] [Related]

  • 16. General pharmacology of the new quinolone antibacterial agent levofloxacin.
    Takasuna K, Kasai Y, Usui C, Takahashi M, Hirohashi M, Tamura K, Takayama S.
    Arzneimittelforschung; 1992 Mar 20; 43(3A):408-18. PubMed ID: 1622443
    [Abstract] [Full Text] [Related]

  • 17. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K, Kimura T, Saeki I, Tabata R, Yamazaki S, Eguchi I, Hanazuka M, Horii D, Munt PL, Davis AS.
    Arzneimittelforschung; 1994 Jun 20; 44(6):715-26. PubMed ID: 8053970
    [Abstract] [Full Text] [Related]

  • 18. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
    Arisawa H, Imai E, Fujise N, Fukui K, Masunaga H.
    Arzneimittelforschung; 2002 Jun 20; 52(1):14-20. PubMed ID: 11838269
    [Abstract] [Full Text] [Related]

  • 19. [Pharmacological studies of an antipschotic agent, penfluridol. (1). The central pharmacological actions].
    Ito K, Nurimoto S, Shintomi K, Kowa Y, Yamamura M, Ishida R.
    Nihon Yakurigaku Zasshi; 1976 Oct 20; 72(7):795-813. PubMed ID: 828132
    [Abstract] [Full Text] [Related]

  • 20. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S, Ikezono K, Umezato M, Hosoki E, Toba Y, Ishikawa M, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct 20; 42(10):1212-22. PubMed ID: 1335257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.